SHANGHAI, China, Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services is pleased to announce today that it has promoted Mr. Edward Hu from Executive Vice President of Operations to Chief Operating Officer.
Prior to joining WuXi PharmaTech in August 2007, Mr. Hu was a senior vice president and Chief Operating Officer at Tanox, Inc., a NASDAQ listed company later acquired by Genentech, Inc. He also worked for Biogen Idec as a business planning manager and for Merck as a senior financial analyst. In the last few months as Executive Vice President of Operations at WuXi PharmaTech, Mr. Hu took many initiatives to strengthen the company's operations and corporate development; he is also instrumental in leading the AppTec acquisition.
"We are very happy to promote Ed to give him more responsibilities, as Ed has quickly demonstrated his leadership capabilities and ability to contribute to the company. Ed will be based in the US to lead the integration of AppTec after the deal is closed," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
Mr. Hu received his MBA and MS in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading
China-based pharmaceutical and biotechnology R&D outsourcing company. As a
research- driven and customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and integrated portfolio
of laboratory and research manufacturing services throughout the drug
discovery and development process. WuXi PharmaTech's services are designed
to assist its global partners in shortening the cycle and lowering the cost
of drug discovery and development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and money. Its
operations are grouped into two segments: laboratory services, consisting
of discovery chemistry, service biology, analytical, toxicology,
pharmaceutical development and process development services, and research
manufacturing, focusing on manufacturing of advanced intermediates and
active pharmaceutical ingredients for R&D use. In 2007, its 80 customers
included nine of the world's top ten pharmaceutical companies by revenue.
For more information, please visit: http://www.wuxipharmatech.com.
For more information, please contact:
|SOURCE WuXi PharmaTech|
Copyright©2008 PR Newswire.
All rights reserved